Racial and Ethnic Disparities in Access to Advanced Therapies for Atopic Dermatitis in the United States

Challenge

Despite racial and ethnic minorities bearing a disproportionate burden of moderate-to-severe AD, they are underrepresented in clinical trials and face documented barriers to accessing advanced systemic therapies. The real-world magnitude of these disparities—and whether they persist after controlling for disease severity and clinical factors—had not been quantified in a large US prospective registry.

Solution

The TARGET-DERM AD registry was used to compare disease severity, comorbidities, and advanced systemic therapy utilization rates across Non-Hispanic White, Non-Hispanic Black, Hispanic, and Non-Hispanic Asian patient groups, with multivariable analyses adjusting for relevant clinical and demographic confounders.